

























CLAIMS






1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:







943	
944	
945	
946	
947	
948	
949	
950	
951	
952	







965	CHIRAL 
966	CHIRAL 
967	CHIRAL 
968	
969	
970	
971	

972	
973	
974	 chiral (+)
975	 chiral (+)
976	CHIRAL 

977	
978	 <p>chiral (-)</p>
979	 <p>chiral (+)</p>
980	
981	

982	
983	
984	
985	
986	
987	





2. A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
3. The pharmaceutical formulation according to claim 2, for use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
4. A compound according to claim 1 for use in therapy.
5. The compound according to claim 1, for use in prevention and/or treatment of mGluR5 receptor-mediated disorders.
6. The compound according to claim 5, wherein the disorder is a neurological disorder.
7. The compound according to claim 5, wherein the disorder is a psychiatric disorder.

8. The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders.
9. The compound according to claim 5, wherein the disorder is a gastrointestinal disorder.
10. The compound according to claim 5, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.
11. The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
12. A method of prevention and/or treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention and/or treatment a therapeutically effective amount of a compound according to claim 1.
13. The method according to claim 12, wherein the disorder is a neurological disorder.

14. The method according to claim 12, wherein the disorder is a psychiatric disorder.
15. The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.
16. The method according to claim 12, wherein the disorder is a gastrointestinal disorder.
17. The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.
18. A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.